Avadel Pharmaceuticals plc (AWK)
XBER 
Summary
AWK Chart
Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
AVDL's board calls Lundbeck's higher $23-per-share bid superior to its Alkermes deal, triggering a critical five-day response window.
New Strong Sell Stocks for Nov. 5
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.
Avadel Pharmaceuticals plc (AWK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Avadel Pharmaceuticals plc ever had a stock split?
Avadel Pharmaceuticals plc Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Gregory J. Divis Jr. CEO | XBER Exchange | IE00BDGMC594 ISIN |
| IE Country | 188 Employees | - Last Dividend | - Last Split | 7 Jun 1996 IPO Date |
Overview
Avadel Pharmaceuticals plc is a biopharmaceutical firm based in the United States, with its headquarters in Dublin, Ireland. Initially founded as Flamel Technologies SA, the company underwent a name change to Avadel Pharmaceuticals plc in January 2017, signaling a new phase in its journey since its incorporation in 2015. The company specializes in developing and delivering pharmaceutical products, focusing on therapies that address unmet medical needs. Avadel Pharmaceuticals plc has carved a niche for itself in the biopharmaceutical industry through its innovative drug development programs and a commitment to improving the lives of patients suffering from various conditions.
Products and Services
- LUMRYZ - This is Avadel Pharmaceuticals plc's lead product candidate, currently in a Phase 3 clinical trial. LUMRYZ is a formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. By targeting these symptoms, LUMRYZ aims to significantly improve the quality of life for individuals affected by narcolepsy, a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep.
Contact Information
